Literature DB >> 2378359

Oral loading of homogentisic acid in controls and in obligate heterozygotes for hereditary tyrosinemia type I.

C Laberge1, A Lescault, A Grenier, J Morrisette, R Gagné, P Gadbois, J Halket.   

Abstract

Homogentisic acid (HGA) (50 mg/kg) was given orally to 22 obligate heterozygotes for hereditary tyrosinemia type 1 (HT) and to 11 controls. After 1 h the mean +/- standard error (SE) plasma level of HGA was 30.42 +/- 1.41 micrograms/ml in carriers and 19.29 +/- 1.62 in controls. Mean +/- SE fasting delta-amino-levulinate dehydratase (delta-ALD) was 40.05 +/- 1.79 m microM/min/g Hb in carriers, much lower than the 60.81 +/- 5.11 found in controls. After 3 h this difference in levels of delta-ALD remained, with mean +/- SE values of 25.70 +/- 2.89 m microM/min/g Hb in carriers, compared with 48.83 +/- 5.37 in controls. Three-hour mean +/- SE excretion of fumarylacetone "equivalent" [FAc] in urine in carriers, 51.597 +/- 5.580 micrograms/mg/creatinine, was significantly higher than the 27.941 +/- 5.916 in controls. Three-hour excretion of succinylacetone "equivalent" [SAc] was also significantly higher in the urine of carriers. FAc in 3-h urine was identified by thin-layer chromatography and confirmed by gas chromatography/mass spectrometry. Multivariate stepwise discriminant analysis showed that the inclusion order of significant variables was as follows: HGA levels at 1 hr, fasting level of delta-ALD, residual level of HGA at 3 h, and 3-h excretion of [FAc]. Non-significant variables were HGA tolerance, levels of delta-ALD at 3 h, sex, and 3-h excretion of [SAc].(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2378359      PMCID: PMC1683732     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  20 in total

1.  Homogentisate metabolism: the isomerization of maleylacetoacetate by an enzyme which requires glutathione.

Authors:  S W EDWARDS; W E KNOX
Journal:  J Biol Chem       Date:  1956-05       Impact factor: 5.157

2.  Purification and properties of delta-aminolevulinate dehydrase from human erythrocytes.

Authors:  P M Anderson; R J Desnick
Journal:  J Biol Chem       Date:  1979-08-10       Impact factor: 5.157

3.  Hereditary tyrosinemia in the province of Quebec: prevalence at birth and geographic distribution.

Authors:  P Bergeron; C Laberge; A Grenier
Journal:  Clin Genet       Date:  1974       Impact factor: 4.438

4.  Purification and properties of maleylacetone cis-trans isomerase from vibrio 01.

Authors:  S Seltzer
Journal:  J Biol Chem       Date:  1973-01-10       Impact factor: 5.157

5.  Hereditary tyrosinemia in a French Canadian isolate.

Authors:  C Laberge
Journal:  Am J Hum Genet       Date:  1969-01       Impact factor: 11.025

6.  Inhibition of delta-aminolevulinic acid dehydrase by 4,6-dioxoheptanoic acid.

Authors:  D P Tschudy; R A Hess; B C Frykholm
Journal:  J Biol Chem       Date:  1981-10-10       Impact factor: 5.157

7.  A study of the determination of 5-aminolevulinate hydro-lyase (delta-aminolevulinate dehydratase) activity in hemolysates of human erythrocytes.

Authors:  H B Collier
Journal:  Clin Biochem       Date:  1971-12       Impact factor: 3.281

8.  Detection of succinylacetone and the use of its measurement in mass screening for hereditary tyrosinemia.

Authors:  A Grenier; A Lescault; C Laberge; R Gagné; O Mamer
Journal:  Clin Chim Acta       Date:  1982-08-04       Impact factor: 3.786

9.  Urinary excretion of succinylacetone and delta-aminolevulinic acid in patients with hereditary tyrosinemia.

Authors:  E Christensen; B B Jacobsen; N Gregersen; H Hjeds; J B Pedersen; N J Brandt; U B Baekmark
Journal:  Clin Chim Acta       Date:  1981-11-11       Impact factor: 3.786

10.  On the enzymic defects in hereditary tyrosinemia.

Authors:  B Lindblad; S Lindstedt; G Steen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

View more
  1 in total

1.  Phenotyping heterozygous carriers of juvenile neuronal ceroid lipofuscinosis with CLN3 mutations.

Authors:  Richard Bergholz; Alfried Kohlschütter; Angela Schulz; Waltraud Hubert; Klaus Rüther
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-10-22       Impact factor: 3.117

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.